-
Something wrong with this record ?
Terbinafine-loaded branched PLGA-based cationic nanoparticles with modifiable properties
J. Martiska, E. Snejdrova, M. Drastik, L. Matysova, M. Dittrich, J. Loskot, P. Jilek,
Language English Country Great Britain
Document type Journal Article
- MeSH
- Antifungal Agents administration & dosage chemistry MeSH
- Administration, Topical MeSH
- Hydrophobic and Hydrophilic Interactions MeSH
- Cations MeSH
- Polylactic Acid-Polyglycolic Acid Copolymer chemistry MeSH
- Nanoparticles chemistry MeSH
- Drug Carriers chemistry MeSH
- Surface-Active Agents chemistry MeSH
- Surface Properties MeSH
- Drug Compounding methods MeSH
- Solubility MeSH
- Terbinafine administration & dosage chemistry MeSH
- Drug Liberation MeSH
- Particle Size MeSH
- Viscosity MeSH
- Publication type
- Journal Article MeSH
Although the systemic administration of terbinafine is quite well tolerated, topical treatment of the local infections is often preferred. New formulation strategies in topical antifungal therapy represent the polymeric nanoparticles (NPs). We successfully employed the originally synthesized PLGA derivatives of branched architectures of various molar masses, branching ratio, and high number of terminal hydroxyl or carboxyl groups for compounding of terbinafine loaded nanoparticles by nanoprecipitation method. Employing the polymers with tailored properties allowed us to formulate the NPs with desired particle size, loading capacity for drug, mucoadhesive properties, and drug release profile. The hydrophobicity and the polyester concentration revealed the main impact on the NPs size ranging from 100 to 600 nm. The stability of the nanosuspension is demonstrated by zeta potential >25 mV, and polydispersity index values <0.2. We used terbinafine in its less dissolved form of the base to increase the drug loading and delay the release. Cationic surfactant as stabilizer give the NPs high positive surface charge enhancing the adhesion to the mucosal surfaces. All formulations provided prolonged sustained release of terbinafine for several days. Antimicrobial potential has been proven by agar-well diffusion method.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023440
- 003
- CZ-PrNML
- 005
- 20201214130040.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10837450.2019.1667387 $2 doi
- 035 __
- $a (PubMed)31509046
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Martiska, Juraj $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 245 10
- $a Terbinafine-loaded branched PLGA-based cationic nanoparticles with modifiable properties / $c J. Martiska, E. Snejdrova, M. Drastik, L. Matysova, M. Dittrich, J. Loskot, P. Jilek,
- 520 9_
- $a Although the systemic administration of terbinafine is quite well tolerated, topical treatment of the local infections is often preferred. New formulation strategies in topical antifungal therapy represent the polymeric nanoparticles (NPs). We successfully employed the originally synthesized PLGA derivatives of branched architectures of various molar masses, branching ratio, and high number of terminal hydroxyl or carboxyl groups for compounding of terbinafine loaded nanoparticles by nanoprecipitation method. Employing the polymers with tailored properties allowed us to formulate the NPs with desired particle size, loading capacity for drug, mucoadhesive properties, and drug release profile. The hydrophobicity and the polyester concentration revealed the main impact on the NPs size ranging from 100 to 600 nm. The stability of the nanosuspension is demonstrated by zeta potential >25 mV, and polydispersity index values <0.2. We used terbinafine in its less dissolved form of the base to increase the drug loading and delay the release. Cationic surfactant as stabilizer give the NPs high positive surface charge enhancing the adhesion to the mucosal surfaces. All formulations provided prolonged sustained release of terbinafine for several days. Antimicrobial potential has been proven by agar-well diffusion method.
- 650 _2
- $a aplikace lokální $7 D000287
- 650 _2
- $a antifungální látky $x aplikace a dávkování $x chemie $7 D000935
- 650 _2
- $a kationty $7 D002412
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a nanočástice $x chemie $7 D053758
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a kopolymer kyseliny glykolové a mléčné $x chemie $7 D000077182
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 650 _2
- $a povrchově aktivní látky $x chemie $7 D013501
- 650 _2
- $a terbinafin $x aplikace a dávkování $x chemie $7 D000077291
- 650 _2
- $a viskozita $7 D014783
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Snejdrova, Eva $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 700 1_
- $a Drastik, Martin $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 700 1_
- $a Matysova, Ludmila $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 700 1_
- $a Dittrich, Milan $u Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 700 1_
- $a Loskot, Jan $u Department of Physics, Faculty of Science, University of Hradec Kralove , Hradec Kralove , Czech Republic.
- 700 1_
- $a Jilek, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University , Prague , Czech Republic.
- 773 0_
- $w MED00004889 $t Pharmaceutical development and technology $x 1097-9867 $g Roč. 24, č. 10 (2019), s. 1308-1316
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31509046 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130040 $b ABA008
- 999 __
- $a ok $b bmc $g 1595759 $s 1114116
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 10 $d 1308-1316 $e 20190925 $i 1097-9867 $m Pharmaceutical development and technology $n Pharm Dev Technol $x MED00004889
- LZP __
- $a Pubmed-20201125